SY-2101

Phase 1Small molecule

SSyros Pharmaceuticals

SY-2101 is one of 37 small molecule programs targeting Acute Promyelocytic Leukemia. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Promyelocytic LeukemiaActive, not recruiting

Acute Promyelocytic LeukemiaPhase 1

Active, not recruiting

Competition

Competitive Landscape

45 competitors in Acute Promyelocytic Leukemia

#DrugCompanyPhaseTrials

Idamycin

Pfizer

Approved

9 2

Cytosar

Teva

Approved

8 3

Trisenox

CCephalon

Approved

20 4

Jakafi

Incyte

Approved

1 5

Scemblix

Istodax

Novantrone

3 8

Cerubidine

HHikma Pharmaceuticals LLC

Approved

1 9

Trexall

Alnylam Pharmaceuticals

Phase 3

8 10

Novantrone

Pfizer

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Acute Promyelocytic Leukemia1 trial

A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia

Suspended·SSyros Pharmaceuticals·Phase 1·NCT04996030·16 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for SY-2101. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SY-2101 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SY-2101. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Syros Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: SSyros Pharmaceuticals

SY-2101

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Acute Promyelocytic Leukemia1 trial

References

Drug Info

Quick Facts

Related News